Pulmonary Arterial Hypertension in Patients Infected with the Human Immunodeficiency Virus.

Abstract

It is important to recognize and treat human immunodeficiency virus-associated pulmonary arterial hypertension (HIV-PAH) because of the associated morbidity and mortality. With the introduction of antiretroviral therapies (ART), improved survival has changed the focus of treatment management from immunodeficiency-related opportunistic infections to chronic cardiovascular complications, including HIV-PAH. The 2018 6th World Symposium of Pulmonary Hypertension recommended a revised definition of PAH that might result in a greater number of patients with HIV-PAH; however, the implication of this change is not yet clear. Here, we review the current literature on the diagnosis, management, and outcomes of patients with HIV-PAH.

• Authors: Stephanie M Hon, Rodolfo M Alpizar-Rivas, Harrison W Farber
• Journal: Cardiology clinics (Cardiol Clin) Vol. 40 Issue 1 Pg. 45-54 (Feb 2022) ISSN: 1558-2264 [Electronic] Netherlands
• PMID: 34809916 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2021 Elsevier Inc. All rights reserved.

Topics

• HIV
• HIV Infections (complications, epidemiology)
• Humans
• Hypertension, Pulmonary (diagnosis, epidemiology, etiology)
• Pulmonary Arterial Hypertension